Get the Stockscreener App
36.79
167.18%
23.02
Pre-market:
35.70
-1.09
-2.96%
Celcuity Inc stock is traded at $36.79, with a volume of 27.54M.
It is up +167.18% in the last 24 hours and up +193.38% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$13.77
Open:
$45.96
24h Volume:
27.54M
Relative Volume:
44.97
Market Cap:
$1.39B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-13.73
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+171.71%
1M Performance:
+193.38%
6M Performance:
+225.86%
1Y Performance:
+96.42%
1-Day Range:
$35.00
$46.42
1-Week Range:
$13.50
$46.42
52-Week Range:
$7.575
$46.42
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
36.79 | 521.42M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity stock price target raised to $50 from $27 at H.C. Wainwright - Investing.com
Celcuity: What’s Happening With CELC Stock? - Forbes
Will Celcuity Inc. continue its uptrendLow Drawdown Stock Screener with Analysis - Newser
Celcuity eyes big market opportunity after breast cancer win - pharmaphorum
Celcuity (NASDAQ:CELC) Given New $50.00 Price Target at HC Wainwright - Defense World
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - Defense World
Leerink Partners Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - Defense World
These 10 Stocks are Winning Big - Insider Monkey
Celcuity announces $225M combined offerings; shares down - MSN
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewswire
Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win - insights.citeline.com
Celcuity rockets after positive trial results on breast cancer combo treatment - Sherwood News
Celcuity announces $225 million in proposed public offerings - Investing.com
Geda load of this: Celcuity rocks breast cancer phase III - BioWorld MedTech
Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success - Invezz
Celcuity Inc (CELC) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Celcuity price target raised to $60 from $28 at Leerink - TipRanks
Celcuity stock rallies on Phase III breast cancer trial progress - Yahoo Finance
Celcuity's triple cancer drug combo beats AstraZeneca in halting cancer progression, shows study - Mint
Celcuity shares triple on late-stage results for breast cancer therapy - BioPharma Dive
Celcuity rockets on new gedatolisib data - The Pharma Letter
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress - ACCESS Newswire
Celcuity Stock (NASDAQ: CELC) shares Skyrockets 210% on Breakthrough Breast Cancer Trial Results | Celcuity Stock Price - paginasiete.bo
Biotech Stock Blasting Off After Late-Stage Trial Results - Schaeffer's Investment Research
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday - 富途牛牛
Celcuity Stock Triples on Positive Breast Cancer Treatment Study - Investopedia
Celcuity's Breast Cancer Drug Trial Shows 210% Stock Surge - AInvest
Celcuity Skyrockets 214%: Can This Biotech Breakout Sustain Momentum? - AInvest
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why - Stocktwits
Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer - Benzinga
Lawmakers demand crackdown on surge in counterfeit weight loss drugs - statnews.com
Why Is Celcuity Stock (CELC) Up 210% Today? - TipRanks
Why is CELC Skyrocketing in Premarket Trading Today? - Tokenist
Celcuity stock soars after breast cancer drug shows 76% risk reduction - Fingerlakes1.com
Celcuity Announces Positive Phase 3 Trial Results - TipRanks
Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study - TradingView
Celcuity's Gedatolisib: A Paradigm Shift in HR+/HER2- Advanced Breast Cancer Treatment - AInvest
Relative strength of Celcuity Inc. in sector analysisFree Earnings Play Trade Plan With Alerts - Newser
Celcuity Soars 112.27% on Positive Breast Cancer Trial Results - AInvest
Celcuity stock soars after breakthrough breast cancer drug trial results By Investing.com - Investing.com Nigeria
Celcuity stock soars after breakthrough breast cancer drug trial results - Investing.com
Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ('PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial - The Manila Times
Celcuity reports breakthrough breast cancer treatment results By Investing.com - Investing.com India
Celcuity reports breakthrough breast cancer treatment results - Investing.com
Breakthrough: New Breast Cancer Drug Quadruples Survival Time in Phase 3 Trial, Sets Historic Efficacy Record - Stock Titan
Does Celcuity Inc. stock perform well during market downturnsFind market-beating stocks for your portfolio - jammulinksnews.com
Celcuity's gedatolisib combo succeeds in pivotal breast cancer study - FirstWord Pharma
Celcuity posts Phase 3 win in breast cancer, setting up challenge to Novartis and Roche - Endpoints News
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - inkl
Celcuity Stock Soars 10.24% Ahead of Breast Cancer Trial Results - AInvest
Can Celcuity Inc. recover in the next quarter Fast Return Equity Forecast With Logic - Newser
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):